Trevi Therapeutics Quarterly Balance Sheet
NASDAQ: TRVIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Trevi Therapeutics financial position
As of Jun 30, 2026, Trevi Therapeutics reported total assets of $330.5 million, up 58.6% from a year earlier against total liabilities of $9.0 million. Shareholders' equity stood at $321.5 million, or 97.3% of assets. The company held $54.3 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 37.28, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Trevi Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 54.30M | 19.41M | 18.91M | 56.87M | 117.06M | 19.37M | 34.10M | 16.05M | 12.96M | 13.81M | 32.40M | 25.96M |
| Short-Term Investments | 264.57M | 152.37M | 169.35M | 138.06M | 86.83M | 83.88M | 73.53M | 49.44M | 56.53M | 59.01M | 50.57M | 62.90M |
| Total Current Assets | 325.70M | 176.12M | 191.66M | 198.30M | 207.23M | 105.62M | 109.43M | 67.34M | 72.13M | 76.77M | 87.55M | 93.95M |
| Property, Plant & Equipment | 336.00K | 265.00K | 178.00K | 213.00K | 239.00K | 277.00K | 157.00K | 174.00K | 198.00K | 204.00K | 216.00K | 238.00K |
| Total Assets | 330.52M | 179.61M | 193.44M | 199.36M | 208.34M | 107.00M | 110.90M | 68.91M | 73.81M | 78.56M | 89.40M | 95.90M |
| Accounts Payable | 3.10M | 2.21M | 3.91M | 2.71M | 2.97M | 1.42M | 3.41M | 1.61M | 1.51M | 2.11M | 1.81M | 1.26M |
| Total Current Liabilities | 8.74M | 7.12M | 9.75M | 9.04M | 9.24M | 6.87M | 10.51M | 9.12M | 6.75M | 5.28M | 5.82M | 5.17M |
| Total Liabilities | 9.01M | 7.48M | 10.20M | 9.57M | 9.85M | 7.55M | 11.26M | 9.94M | 7.64M | 6.22M | 6.86M | 6.29M |
| Shareholders' Equity | 321.51M | 172.13M | 183.24M | 189.79M | 198.49M | 99.46M | 99.64M | 58.97M | 66.17M | 72.33M | 82.55M | 89.61M |
| Retained Earnings | -360.79M | -343.00M | -329.80M | -321.49M | -309.69M | -297.38M | -287.05M | -275.63M | -262.39M | -250.04M | -239.13M | -231.31M |
| Net Cash (Debt) | 318.87M | 171.78M | 188.26M | 194.93M | 203.88M | 103.26M | 107.62M | 65.49M | 69.50M | 72.82M | 82.97M | 88.87M |
| Shares Outstanding | 142.42M | 128.41M | 128.31M | 128.22M | 121.78M | 99.89M | 93.60M | 75.45M | 72.59M | 68.96M | 68.28M | 63.86M |
This table shows 12 quarterly periods of Trevi Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 13 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow TRVI's reporting calendar. What is a balance sheet?